Current Molecular Pharmacology earns dual Q1 rankings with 2025 impact factor of 7.2
FAR Publishing Limited
Following the release of the 2025 Journal Citation Reports on June 17, 2026, Current Molecular Pharmacology (CMP) has achieved a notable milestone with its Impact Factor rising to 7.2. This marks a significant enhancement in the journal's scholarly impact and global recognition.
In the Biochemistry & Molecular Biology category, CMP now ranks 46th out of 328 journals, securing a Q1 position. Meanwhile, in the Pharmacology & Pharmacy category, the journal ranks 32nd out of 356, also attaining Q1 status. These concurrent top-quartile placements reflect the journal's broad-based academic elevation and increased international visibility across both core disciplines.
The editorial team extends its sincere gratitude to the global board members, reviewers, authors, and readers whose unwavering support has made this achievement possible. Looking forward, CMP remains committed to advancing molecular pharmacology research and continuing to serve as a trusted platform for impactful scientific contributions.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.